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Abstract
Background: To date, no studies have examined the extent of knowledge and perceptions of Good Samaritan
Laws (GSLs) among young adults who engage in non-medical prescription opioid (NMPO) use. We sought to
determine awareness of and factors associated with knowledge of Rhode Island’s Good Samaritan Law (RIGSL)
among young adult NMPO users.
Findings: We compared the sociodemographic and overdose-related characteristics of participants who were
aware and unaware of the RIGSL and determined independent correlates of knowledge of the RIGSL via modified
stepwise logistic regression. Among 198 eligible participants, 15.7 % were black, 62.1 % white, and 20.7 % mixed or
other race. The mean age was 24.5 (SD = 3.2) and 129 (65.2 %) were male. Fewer than half (45.5 %) were aware of
the RIGSL; nonetheless, the majority (95.5 %) reported a willingness to call 911 in the event of an overdose.
Knowledge of the RIGSL was associated with older age, white race, a history of incarceration, a history of injection
drug use, lifetime heroin use, ever witnessing or experiencing an overdose, having heard of naloxone, knowledge
of where to obtain naloxone, and experience administering naloxone (all p < 0.05). In the final explanatory
regression model, lifetime injection drug use, having heard of naloxone, and knowledge of where to obtain
naloxone were independently associated with awareness of the RIGSL.
Conclusions: Fewer than half of NMPO users surveyed knew of the RIGSL. Targeted harm reduction education is
needed to address a vulnerable population of NMPO users who have not initiated injection drug use and are
unaware of naloxone. Additional research is needed to determine how the effectiveness of GSLs could be
improved to prevent overdose deaths among young adults.
Keywords: Good Samaritan Law, Opioid, Non-medical prescription opioid, Young adult, Overdose
Introduction
Since the early 2000s, non-medical prescription opioid
(NMPO) use and heroin use have resulted in dramatic-
ally escalating rates of unintentional drug overdose
across the USA [1, 2]. In response to the ongoing
nationwide opioid epidemic, a number of US states have
implemented harm reduction programs and legislative
policies focused on reducing the occurrence of fatal
opioid overdose, including prescription monitoring
programs, laws restricting new prescriptions for opioid
medications, training programs for opioid users to
recognize overdose, and equipping first responders and
community outreach organizations with naloxone [3–5].
As of 2015, 34 US states and the District of Columbia
had also enacted limited opioid amnesty laws [6]. The
objective of such laws is to encourage persons who
witness an overdose to contact emergency personnel,
even if there are controlled substances at the scene.
Rhode Island’s Good Samaritan Overdose Prevention
Act, R.I. Gen. Laws §21-28.8-4 (2012), first enacted in
2012 and reinstated in 2016, grants limited legal immun-
ity to anyone who seeks or receives medical assistance
for a drug-related overdose or medical emergency,
unless that person is involved with the manufacture
and/or distribution of controlled substances. Specifically,
the law protects “Any person who, in good faith, without
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malice and in the absence of evidence of an intent to
defraud seeks medical assistance for someone experien-
cing a drug overdose or other drug-related medical
emergency shall not be charged or prosecuted for any
crime under RIGL 21–28 or 21–28.5, except for a crime
involving the manufacture or possession with the intent
to manufacture a controlled substance or possession
with intent to deliver a controlled substance, if the
evidence for the charge was gained as a result of the
seeking of medical assistance” [7]. Notably, the 2016
version of the law provides immunity to individuals on
probation or parole (i.e., seeking medical assistance in
the event of an overdose is not a violation of the terms
of probation/parole).
Young adults who engage in NMPO use are a high-
risk subpopulation of opioid users [8, 9]. They are
often in the process of developing long-lasting and
potentially life-altering patterns of polysubstance and
opioid use; furthermore, young adults who engage in
casual experimentation with NMPO use may transi-
tion to heroin and injection drug use [10–12]. Many
harm reduction services, including syringe exchange
and overdose education programs, have primarily tar-
geted adult and/or NMPO users who use heroin and/
or inject drugs [3, 13–18]. Therefore, young opioid
users who are experimenting with NMPO use are at
high risk for overdose but may have received less
harm reduction education and, as a result, may not
know how to react to an overdose and may be
unaware of the legal protections afforded by Good
Samaritan Laws (GSLs) [19].
Frequently skeptical of authority (in light of the
often punitive legal consequences associated with her-
oin and opioid possession), young adults also face
perceived and systemic deterrents that may prevent
them from contacting emergency personnel in the
event of an opioid overdose [20]. To date, no studies
have examined the extent of knowledge and percep-
tions of GSLs among young adult NMPO users. This
study represents an initial assessment of the aware-
ness of Rhode Island’s GSL (RIGSL), R.I. Gen. Laws
§21-28.8-4 (2012), among 18–29-year-old NMPO
users. Due to the socially and legally sensitive nature
of the raw data, the minimum eligible age (18 years)
was selected in order to include the perspectives of
the youngest possible adults able to autonomously
provide legal consent (in the state of Rhode Island) to
participate in a sensitive public health research study.
To be consistent with previously published research
[21, 22], we defined the maximum age limit for the
term “young adult” to be 29 years of age. The pri-
mary objective of the analysis was to assess the socio-
demographic and behavioral factors associated with
knowledge of the RIGSL.
Methods
Participants were recruited from January 2015 through
February 2016 through online venues (e.g., Craigslist),
bus advertisements, word of mouth, flyers, and referrals.
Eligible participants were Rhode Island (RI) residents
between the ages of 18 and 29 who had engaged in
NMPO use within 30 days prior to their interview.
NMPO use was defined as consuming a prescription
opioid that was not prescribed by a licensed medical
provider, or as using a prescription opioid with a differ-
ent mode of administration (e.g., snorted, injected) or
dosage than was prescribed. Surveys included questions
about drug-related risk behavior, sexual history, employ-
ment and housing status, and NMPO and polysubstance
use. A trained interviewer administered all survey ques-
tions except those related to injection drug use, which
were administered via computer-assisted personal inter-
viewing (CAPI). Participants received $25 upon complet-
ing the hour-long survey. Between January 2015 and
June 2015, we attempted to recruit participants through
respondent-driven sampling (RDS). The RDS approach
was terminated in June 2015 due to the limited referral
of eligible participants from their peers who completed
the survey; no other peer drug users were involved in
the recruitment of study participants.
This study received approval from a research ethics
committee, the Brown University Institutional Review
Board (IRB #1403001006), and conforms to the standards
outlined in the Declaration of Helsinki. Participants volun-
tarily signed informed consent forms prior to completing
a confidential survey.
The primary outcome relevant to this analysis was:
“Have you ever heard of Rhode Island’s Good Samaritan
Law?” Descriptive statistics and frequencies were used to
compare the characteristics of the participants who were
aware and unaware of the RIGSL. Pearson’s χ2 tests and
Fisher’s exact tests (for any cell counts <5) were used to
determine associations between knowledge of the RIGSL
and the variables listed in Table 1, which are related to
injection drug use, heroin and NMPO use, experienced
and witnessed opioid overdose, and naloxone access and
harm reduction knowledge. We also assessed the will-
ingness of participants to recruit emergency services by
asking “Would you call 911 if you or someone you knew
was overdosing, even if drugs were present at the
scene?” prior to asking them if they were aware of the
RIGSL. Finally, among participants who had overdosed
in the last 6 months, we examined the actual actions
that bystanders had taken to mitigate instances of opioid
overdose (e.g., calling 911, administering naloxone).
We used a modified backward stepwise regression pro-
cedure [23, 24] to build an explanatory multivariate
model and to identify variables independently correlated
with knowledge of the RIGSL. In brief, variables listed in
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Table 1 with p < 0.20 were included in the initial model
(variables in Table 2 were not considered due to low
response counts). The covariate with the highest type III
p value was eliminated in subsequent rounds of regres-
sion. The model with the lowest Akaike information
criterion (AIC) was selected as the final model. R version
3.2.3(C) 2015 was used for all statistical analysis, and all
p values were two-sided.
Results
Out of 200 total recruited participants, 198 (99 %)
answered the question “have you ever heard of Rhode
Island’s Good Samaritan Law?” and were included in the
analysis. The mean age of the sample was 24.5 years
(SD = 3.2), 129 (65.2 %) were male, and 14.1 % identified
their ethnicity as Hispanic or Latino. In addition, the
eligible sample was 15.7 % black (African American or
of African, Haitian, or Cape Verdean descent), 62.1 %
white, and 20.7 % were of mixed or other race.
Among eligible participants, 90 (45.5 %) reported
awareness of the RIGSL. Knowledge of the RIGSL varied
by race: 53.7 % of white, 29.0 % of black, and 34.1 % of
other/mixed race participants reported being aware of
the RIGSL (p = 0.012). Other sociodemographic factors
associated with awareness of the RIGSL included older
age, prior incarceration, and history of homelessness
(see Table 1). A sub-analysis of drug use behaviors by
race showed that white participants had the highest
prevalence of lifetime heroin use (61.8 versus 11.1 % for
black and mixed/other race participants, p < 0.001),
lifetime injection drug use (44.3 versus 5.6 % for black
and mixed/other race participants, p < 0.001), and
Table 1 Factors associated with knowledge of the RIGSL
among young adult NMPO users (n = 198)
















Male 129 (65.2) 64 (49.6) 65 (50.4) 0.145
Female 69 (34.8) 26 (37.7) 43 (62.3)
Ethnicity
Not Hispanic or Latino 170 (85.9) 77 (45.3) 93 (54.7) 0.911




31 (15.7) 9 (29.0) 22 (71.0) 0.012
White 123 (62.1) 66 (53.7) 57 (46.3)
Aggregated “all other races” 41 (20.7) 14 (34.1) 27 (65.9)
Education
Some high school or less 23 (11.6) 8 (34.8) 15 (65.2) 0.558b
Finished high school or GED 75 (37.9) 34 (45.3) 41 (54.7)
Some college 74 (37.4) 35 (47.3) 39 (52.7)
Trade or technical school 7 (3.5) 5 (71.4) 2 (28.6)
College or university degree 19 (9.6) 8 (42.1) 11 (57.9)
History of incarceration
Yes 73 (36.9) 52 (55.9) 41 (44.1) 0.008
No 105 (53.0) 38 (36.2) 67 (63.8)
History of homelessness
Yes 108 (54.5) 57 (52.8) 51 (47.2) 0.034
No 90 (45.5) 33 (36.7) 57 (63.3)
Lifetime injection drug use
Yes 59 (29.8) 43 (72.9) 16 (27.1) <0.001
No 138 (69.7) 46 (33.3) 92 (66.7)
Lifetime heroin use
Yes 85 (42.9) 55 (64.7) 30 (35.3) <0.001
No 113 (57.1) 35 (31.0) 78 (69.0)
Ever witnessed an overdose
Yes 102 (51.5) 55 (53.9) 47 (46.1) 0.020
No 96 (48.5) 35 (36.5) 61 (63.5)
Ever experienced an overdose
Yes 53 (26.8) 32 (60.4) 21 (39.6) 0.017
No 145 (73.2) 58 (40.0) 87 (60.0)
Have you ever heard of
Narcan™, otherwise known
as naloxone?
Yes 120 (60.6) 75 (62.5) 45 (37.5) <0.001
No 78 (39.4) 15 (19.2) 63 (80.8)
Table 1 Factors associated with knowledge of the RIGSL
among young adult NMPO users (n = 198) (Continued)
Do you know where to buy
or obtain Narcan™?
Yes 82 (41.4) 60 (73.2) 22 (26.8) <0.001
No 116 (58.6) 30 (25.9) 86 (74.1)
Have you ever administered
Narcan™ to someone you
thought was overdosing?
Yes 21 (10.6) 16 (76.2) 5 (23.8) 0.006
No 177 (89.4) 74 (41.8) 103
(58.2)
Would you call 911 in the
event of an overdose, even if
there were drugs at the scene?
Yes 189 (95.5) 87 (46.0) 102
(54.0)
0.729b
No 8 (4.0) 3 (37.5) 5 (62.5)
aWelch’s t test
bFisher’s exact test
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history of overdose (36.6 versus 9.7 % for black and
mixed/other race participants, p < 0.001).
A trend emerged in which participants with more
extensive drug use profiles were (proportionally) more
aware of the RIGSL. For example, of the 59 NMPO users
who had ever injected drugs, 72.9 % were aware of the
RIGSL, whereas only 33.3 % of non-injectors were aware
of the RIGSL (p < 0.001). This trend held for heroin use,
with 64.7 % of participants who had tried heroin and
only 31.0 % who had not tried heroin reporting aware-
ness of the RIGSL (p < 0.001). Having ever experienced
an overdose and having ever seen someone overdose
were also both associated with awareness of the RIGSL
(both p < 0.05, see Table 1).
Several measures of harm reduction education (e.g.,
having ever heard of naloxone, knowing where naloxone
could be obtained, and having ever administered nalox-
one) were significantly and positively associated with
knowledge of the RIGSL (all p < 0.05). In addition, the
vast majority of participants (95.5 %) reported a willing-
ness to call 911 in the event of an overdose-related
emergency even if there were drugs at the scene. How-
ever, among the 189 NMPO users surveyed who re-
ported willingness to call 911, only 46.0 % were aware of
the GSL, and knowledge of the GSL was not associated
with a willingness to call 911 (p = 0.729).
The final explanatory multivariate model with the low-
est AIC included the following covariates: history of
injection drug use (APR = 1.29, 95 % CI 1.01–1.57, p =
0.064), having heard of naloxone (APR = 1.88, 95 % CI
1.28–2.49, p = 0.071), and knowledge of where to obtain
naloxone (APR = 1.73, 95 % CI 1.29–2.17, p = 0.002).
Lastly, among the 21 participants who experienced an
opioid overdose within 6 months of completing the sur-
vey, 14 (66.7 %) were aware of the RIGSL. Of note, all
six individuals who reported having an individual call
911 the last time they overdosed were aware of the
RISGSL. However, we have no data indicating that the
individuals who actually dialed 911 in response to these
(six) particular overdose situations were aware of the
RIGSL. Of the 12 individuals who reported naloxone
being administered the last time they overdosed, 9 (75.0 %)
were aware of the RIGSL. Other reactions to individuals’
most recent overdose stratified by knowledge of the RIGSL
are shown in Table 2.
Discussion
In this study of young adult NMPO users in RI, know-
ledge of the RIGSL was moderately high but unevenly
distributed across the study population. Despite this,
participants reported nearly universal willingness to
recruit 911 in the event of an opioid emergency. Know-
ledge of the RIGSL was less common among young
NMPO users who had not used heroin, injected drugs,
or witnessed or experienced an overdose.
Given these findings, it is possible that young adult
NMPO users in RI first learn about the RIGSL after
experiencing or witnessing an overdose. A second pos-
sible explanation is that harm reduction programs
(which provide naloxone education, overdose training,
and injection equipment) may educate their high-risk
clientele about the protections afforded by GSLs. In fact,
knowledge of where naloxone could be obtained was the
strongest correlate of awareness of the RIGSL. Other
covariates included in the final model (history of injec-
tion drug use, having heard of naloxone) also support
the assertion that young NMPO users in RI (and likely
also their opioid using peers) may currently be receiving
education about the RIGSL through harm reduction out-
lets that provide naloxone and injection equipment.
Over 95 % of the study participants reported willing-
ness to call 911 in the event of an overdose, despite the
fact that fear of arrest has historically been a primary
Table 2 Responses to recent overdoses and knowledge of the
RIGSL among young adult NMPO users who reported
experiencing an overdose in the past 6 months (n = 21)






The last time you overdosed,
were you alone?
Yes 4 (19.0) 1 (25.0) 3 (75.0)
No 17 (81.0) 13 (76.5) 4 (23.5)
Did someone call 911 the last
time you overdosed?b
Yes 6 (28.6) 6 (100.0) 0 (0.0)
No 11 (52.4) 7 (63.6) 4 (36.4)
The last time you overdosed,
were you taken to a hospital?
Yes 8 (38.1) 7 (87.5) 1 (12.5)
No 13 (61.9) 7 (53.8) 6 (46.2)
The last time you overdosed,
did someone administer naloxone?
Yes 12 (57.1) 9 (75.0) 3 (25.0)
No 6 (28.6) 4 (66.7) 2 (33.3)
Who administered the naloxone
(the last time you overdosed)?c
A police officer 4 (19.0) 3 (75.0) 1 (25.0)
An ambulance official 2 (9.5) 2 (100.0) 0 (0.0)
A friend 3 (14.3) 2 (66.7) 1 (33.3)
A parent or relative 1 (4.8) 0 (0.0) 1 (100.0)
Someone else 2 (9.5) 2 (100.0) 0 (0.0)
Note: “Recent overdoses” were those that occurred within the last 6 months
aNot all columns add to 100 % due to missing values
bOf those who had experienced an overdose in the past 6 months and were
not alone when they overdosed
cOf those who had experienced an overdose in the past 6 months and were
treated with naloxone
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reason for failing to contact emergency medical services
during an overdose [25]. In RI, a recent study showed
high levels of knowledge of RIGSL among police officers
and near universal awareness of the protections afforded
by the RIGSL among those who received opioid over-
dose training [26]. It is possible that these educational
and outreach efforts with law enforcement personnel,
and as well considerable media coverage encouraging in-
dividuals to contact emergency services in the event of
an overdose, have led to a high level of willingness to
call 911 in this setting.
In light of these findings, it is important to consider
how the RIGSL could be made more effective, even
when NMPO-using young adults are aware of the GSL.
For example, the physiological consequences of opioid
overdose may render individuals who overdose alone
physically unable to recruit help or emergency services.
It follows that the effectiveness of the RIGSL likely
depends, in part, on the degree to which individuals en-
gage in social (or monitored) NMPO use. Of the 21 par-
ticipants who reported a recent overdose, 4 (19.0 %)
were alone. Thus, interventions may be needed to
encourage young adults who use prescription opioids
non-medically to avoid doing so alone, in addition to
campaigns promoting the protections afforded by GSLs.
A recent report showed that targeting naloxone educa-
tion programs to nearly 3000 bystanders (individuals who
might have contact with NMPO and heroin users) suc-
cessfully decreased the rate of fatal opioid overdose in 19
towns across Massachusetts [3]. Given these results, it
may be prudent to target education about the RIGSL to
bystanders (i.e., close friends and family of young NMPO
users), as well as to young NMPO users themselves, in
order to improve the efficacy of the RIGSL.
This analysis should be considered in light of several
limitations. First, underreporting of socially undesirable
behaviors (e.g., ever using heroin, ever injecting, being
unwilling to call 911 in response to a potentially fatal
overdose) is possible. Second, the small sample size
impeded robust examination of the relationship between
knowledge of the RIGSL and the actions participants
took in response to recent overdoses. Finally, although
multiple online and field-based methods were used to
recruit study participants, the findings may not necessar-
ily be generalizable to all young adult NMPO users in
RI. Unfortunately, to our knowledge, no other studies
have examined NMPO use among young adults in RI or
other states in the New England region. Future studies
are needed to confirm whether this sample is representa-
tive of the target population.
In sum, we observed moderate levels of awareness of a
GSL among young adults who use prescription opioids
non-medically in RI. Targeted harm reduction education
(concerning the RIGSL but also general overdose
prevention and response training) may be needed to ad-
dress a vulnerable population of NMPO users who have
not initiated injection drug or heroin use. Additional
research is needed to determine how the effectiveness of
GSLs could be improved to prevent overdose deaths
among young adults.
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